VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The impact of the FDA approval of pemigatinib

In this video, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly highlights the impact of the recent FDA approval of pemigatinib for the treatment of adult patients with relapsed/refractory (R/R) myeloid/lymphoid neoplasms with FGFR1 rearrangement. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter